Physician profile
Lien B Lam
NPI 1447345418
$1,852.18
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $225 · 2021: $237 · 2022: $689 · 2023: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $229.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $295.54 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $270.70 | 2019-2023 | Farxiga |
| Allergan, INC. | $123.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.72 | 2019-2022 | |
| Amarin Pharma, INC. | $107.39 | 2019-2022 | |
| Glaxosmithkline, LLC. | $94.55 | 2019-2022 | |
| Abbvie INC. | $91.41 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $76.91 | 2022 | |
| Pfizer INC. | $75.26 | 2019-2023 | |
| Lilly USA, LLC | $73.99 | 2022-2023 | Mounjaro |
| Upsher-Smith Laboratories LLC | $54.95 | 2022 | |
| Esperion Therapeutics, INC. | $54.76 | 2021-2022 | |
| Abbott Laboratories | $52.18 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $51.04 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $49.99 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $39.83 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $27.86 | 2022 | |
| Amgen INC. | $26.21 | 2019-2022 | |
| Si-Bone, INC. | $24.59 | 2020 | |
| Merck Sharp & Dohme LLC | $23.44 | 2019-2020 | |
| Exact Sciences Corporation | $21.37 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $18.70 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.67 | 2022 | |
| Axsome Therapeutics, INC. | $18.59 | 2023 | Auvelity |
| Jazz Pharmaceuticals INC. | $17.63 | 2021 | |
| Antares Pharma, INC. | $17.31 | 2023 | Tlando, Xyosted, Nocdurna |
| Aytu Biopharma, INC. | $15.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lien Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.